Anticoagulant Reversal Drugs Market is Projected to Grow at A CAGR of 16.5% During, 2020-2026

ABOUT THIS REPORT

OVERVIEW

Anticoagulant Reversal Drugs Market was valued at $822.5 million in 2019 with a CAGR of 16.5% from 2020 to 2026.

Anticoagulant reversal drugs are used when the anticoagulant drug needs to be reversed the side effect such as bleeding complications, an overdose of the anticoagulant drug, or unplanned surgery. Some of the commercialized anticoagulant reversal drugs include Prothrombin Complex Concentrates (PCC), Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, AndeXXa.

Increasing regulatory approval for anticoagulant reversal drugs is the major driving factor for the market. For instance, The U.S. Food and Drug Administration (FDA) has approved Andexxa, the first factor Xa inhibitor antidote for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis). Andexxa is used for reversal of anticoagulation due to life-threatening or uncontrolled bleeding. Andexxa has received both U.S. orphan drug and FDA breakthrough therapy designations. The approval of Andexxa is supported by Phase 3 ANNEXA studies, which indicate the safety and efficacy of Andexxa in reversing the anticoagulant drug of the factor Xa inhibitors rivaroxaban and apixaban in healthy volunteers. Further, the risk associated with anticoagulant drugs is a key driving factor of the market. Anticoagulant reversal drugs are used to reverse or neutralized the side effect of the anticoagulant drug. Some of the anticoagulant drugs include rivaroxaban, apixaban, dabigatran, warfarin, and more. Rivaroxaban and apixaban are anticoagulants used to reduce blood clotting and systemic embolism in patients with atrial fibrillation but can cause certain side effects including uncontrolled bleeding in the nose, bruise, blood in the urine, or bleeding gums. The incidence of bleeding side effects at rare occasions can be serious or even life-threatening. Andexxa is an antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis). Dabigatran (Pradaxa) is an anticoagulant drug, help to reduce the risk of stroke in AFib. Dabigatran major side effect can cause life-threatening and uncontrolled bleeding. Praxbind (idarucizumab) is a specific reversal agent for Pradaxa. Praxbind helps to reverse the anticoagulant effects for emergency surgical procedures or uncontrolled bleeding.

Prothrombin Complex Concentrates (PCC), Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, AndeXXa, and Others is the type segment of the market scope. By application, the market is divided into Hospital Pharmacies, Retail Pharmacies, and Others. The report covers value of the global market by type and application.

Vitamin K was dominating the global anticoagulant reversal drugs in 2019, owing to the partnership between companies to conduct clinical trials for anticoagulant reversal drugs commercialization of regulatory approved anticoagulant reversal drugs.

North America, Europe, Asia Pacific, South America, and Middle East & Africa are taken into consideration at the global anticoagulant reversal drugs value figures. While North America is further categorized into enhancing the United States, Canada, and Mexico, Europe is split into the United Kingdom, Germany, France, Italy, and Rest of Europe. Asia-Pacific covers India, China, Japan, South Korea, and Rest of Asia Pacific in its scope. South America is bifurcated into Brazil, Argentina, and Rest of South America, with Middle East & Africa involving GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the global anticoagulant reversal drugs market in 2019, due to the increasing number of clinical studies for anticoagulant reversal drugs, the partnership between companies to collaboratively develop anticoagulant reversal drugs and regulatory approval for increasing large-scale commercial production of Andexxa.

Major players operating in the anticoagulant reversal drugs industry include Bausch Health Companies, Inc., Fresenius Kabi AG, Boehringer Ingelheim GmbH, Amneal Pharmaceuticals, Inc., CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Cadila Healthcare, and Pfizer Inc.

The commercialization of regulatory approved anticoagulant reversal drugs, increasing clinical studies on anticoagulant reversal drugs, the collaboration between companies to develop reversal drugs, and strategic acquisition to expand the product portfolio with anticoagulant reversal drugs are some of the strategies adopted by the major companies.